Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medplus Health Services has informed exchanges that its subsidiary, Optival Health Solutions Private Limited, received a two-day suspension order for the drug license of a store located in Rampure Colony, Bidar, Karnataka. The order was issued by the Assistant Director, Drugs Control Administration, Bangalore Circle – Bidar, on August 1, 2025, under Rule 65 of the Drugs and Cosmetics Act, 1940. The action pertains to a single retail outlet and does not impact other stores. The company has disclosed a potential revenue loss of approximately Rs 0.18 lakhs (around Rs 18,000) from this suspension. The filing was made under SEBI's Regulation 30 disclosure requirements.
The financial impact is negligible, limited to roughly Rs 18,000 in lost revenue from a single store over two days. This is a routine regulatory compliance matter with no material effect on the company's overall operations or financials, and is unlikely to move the stock price.